Elite Pharmaceuticals, Inc. (AMEX: ELI) has completed the first stage of its Phase II study for ELI-216 and is preparing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE